Alnylam Pharmaceuticals
ALNY
Market cap $31.7B

245.44 USD

+6.57

2.75%

At close Dec 20, 4:00 PM EST

After hours

245.44

+0.00

0.00%

1 day

2.75%

5 days

-0.41%

1 month

-1.35%

3 months

-10.38%

6 months

55.93%

Year to date

25.91%

1 year

37.08%

5 years

111.71%

10 years

139.50%

About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Employees: 2,100

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 12 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

57% more first-time investments, than exits

New positions opened: 105 | Existing positions closed: 67

26% more repeat investments, than reductions

Existing positions increased: 212 | Existing positions reduced: 168

17% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]

14% more capital invested

Capital invested by funds: $29.3B [Q2] → $33.4B (+$4.08B) [Q3]

12% more call options, than puts

Call options by funds: $364M | Put options by funds: $325M

7% more funds holding

Funds holding: 515 [Q2] → 553 (+38) [Q3]

0.76% less ownership

Funds ownership: 95.41% [Q2] → 94.65% (-0.76%) [Q3]

See Fund Rankings

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$220

10%

downside

Avg. target

$320

30%

upside

High target

$400

63%

upside

12 analyst ratings

11 positive

92%

1 neutral

8%

0 negative

0%

Piper Sandler Edward Tenthoff 23% 1-year accuracy 10 / 43 met price target	21%upside $296	Overweight Reiterated	18 Nov 2024
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target	63%upside $400	Buy Reiterated	18 Nov 2024
Raymond James Gary Nachman 54% 1-year accuracy 7 / 13 met price target	21%upside $298	Outperform Maintained	1 Nov 2024
RBC Capital Luca Issi 27% 1-year accuracy 15 / 56 met price target	22%upside $300	Outperform Reiterated	1 Nov 2024
Scotiabank Greg Harrison 33% 1-year accuracy 9 / 27 met price target	26%upside $310	Sector Outperform Maintained	1 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ALNY published over the past 30 days

Zacks Investment Research

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Zacks Investment Research

What Makes Alnylam (ALNY) a New Buy Stock

Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Alnylam (ALNY) a New Buy Stock

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available.

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

Zacks Investment Research

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental New Drug Application (sNDA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Based on the Company's use of a Priority Review Voucher, the FDA has set an action date goal of Mar.

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Zacks Investment Research

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran (formerly ALN-TTRsc04), a next-generation RNAi therapeutic in development for the treatment of transthyretin (ATTR) amyloidosis. The data were presented in an oral session at the American Heart Association Scientific Sessions 2024 in Chicago. These new results demonstrated that a single dose o.

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: UBS Global Healthcare Conference on Tuesday, November 12, 2024 at 8:45 am PT (11:45 ET) at the Terranea Resort in Ranchos Palos Verdes, CA Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:30 am GMT (4:30 am ET) in London A live audio webcast of each presentat.

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Zacks Investment Research

Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down

ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.

Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down

The Motley Fool

Alnylam's Revenues Drop Sharply in Q3

Alnylam Pharmaceuticals' product revenues grew at a healthy pace, but on other fronts, it struggled.

Alnylam's Revenues Drop Sharply in Q3

See News Rankings

Charts implemented using Lightweight Charts™